Cheney blasts device tax as one of 'the dumbest ideas' ever; Aurora Spine wins 510(k);

@FierceMedDev: That didn't take long: Myriad Genetics targets LabCorp with BRCA patent suit. Item | Follow @FierceMedDev

@MarkHFierce: DioGenix pulled in $3.2M in private financing to fuel continued work on its MS diagnostic test. Release | Follow @MarkHFierce

@MichaelGFierce: BioDelivery Sciences is moving ahead on its #diabetes pain gel with the FDA's blessing. Story | Follow @MichaelGFierce

@GalenMoore: Medtronic's new version of Symplicity gets a green light in EU and Australia. Release | Follow @GalenMoore

> DioGenix pulled in $3.2 million in a new private financing designed to fund an ongoing clinical trial of its new multiple sclerosis diagnostic. Item

> Former U.S. Vice President Dick Cheney termed the medical device tax as one of "the dumbest ideas" he has ever heard. Story

> California's Aurora Spine nailed down a 510(k) clearance for a new spinal fixation device for spinal fusion procedures. Item

> BSD Medical ($BSDM) said it has started selling its microwave ablation systems in Turkey, via a distributor. Item

> KUOW details how a recalled drug infuser made by the German company B. Braun malfunctioned and killed an ailing Seattle jazz musician. Story

Biotech News

@FierceBiotech: I-SPY a controversy over Puma's positive PhII test of neratini. Story | Follow @FierceBiotech

@JohnCFierce: My favorite dysfunctional pharma company, Eli Lilly, reports yet another PhIII flop. Release | Follow @JohnCFierce

@DamianFierce: If Transcept can't find a buyer, it's going to liquidate come Q2. Release | Follow @DamianFierce

@EmilyMFierce: Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. News | Follow @EmilyMFierce

> Lilly extends its streak of PhIII failures, scraps another program. More

> PaxVax snags $22M to get fast-tracked cholera pill through Phase III. Story

> FDA questions safety of Takeda's blockbuster-hopeful bowel disease drug. Article

Pharma News

@FiercePharma: GSK fends off wrongful death case alleging Paxil led to abortion. News | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years--150 in U.S.--now that it owns Agila. Story | Follow @EricPFierce

@CarlyHFierce: SEC: Provenge critic lied about her bets Dendreon stock would fall. Yesterday's story | Follow @CarlyHFierce

> Sanofi's MS drug Lemtrada tripped up again, this time in U.K. More

> Pfizer fights Hanmi in Korea over its Viagra design. Story

Vaccines News

> The argument for vaccinating: 100M cases of disease prevented in U.S. Story

> Nonprofit crowdfunding tech-enabled HIV vaccine project. Piece

> Whooping cough vaccine fails to stop spread of disease in FDA animal study. More

> TB vaccine shows promise in preventing MS. News

> CDC considers expanding use of Bexsero as meningitis outbreak spreads. Article

> PaxVax raises $22M for PhIII trial of cholera vaccine. Item

Pharma Manufacturing News

> In cancer immunotherapy joint venture, Fred Hutch and MSKCC face manufacturing challenges. Piece

> Pfizer whacking 150 jobs in closure of Irish packaging plant. News

> FDA warning letter tasks Wockhardt with global plant assessment. More

> PhRMA begins another lawsuit against a drug-disposal law. Story

> Boehringer taps BofA to talk up potential of sterile injectables plant. Article

> Patheon invests in U.K. plant, posts operating loss. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.